# Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).

> **NCT07471789** · PHASE1,PHASE2 · RECRUITING · sponsor: **Gyala Therapeutics** · enrollment: 33 (estimated)

## Conditions studied

- Acute Myeloblastic Leukaemia
- Leukemia, T-Cell

## Interventions

- **DRUG:** CART84

## Key facts

- **NCT ID:** NCT07471789
- **Lead sponsor:** Gyala Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-04
- **Primary completion:** 2029-05-31
- **Final completion:** 2031-02-04
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07471789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07471789, "Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07471789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*